Description
Background:
Vobarilizumab is a humanized bispecific nanobody (Llama-derived heavy-chain only (Vhh) antibody) designed for the treatment of inflammatory autoimmune diseases.
This drug was developed to block interleukin-6 receptor. Vobarilizumab has been evaluated in patients with rheumatoid arthritis as well as in Lupus
Intended Use:
For Estimation of Vobarilizumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!